VVOS
Vivos Therapeutics, Inc.2.0200
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
18.16MP/E (TTM)
-Basic EPS (TTM)
-1.77Dividend Yield
0%Recent Filings
8-K
Johnson joins Vivos board
Vivos Therapeutics appointed Gregg C. E. Johnson as an independent director effective February 4, 2026, adding him to the Compensation Committee. Johnson, a former company secretary and director with deep experience in law, compliance, capital markets, and scaling public ventures—including NASDAQ listings—brings proven expertise. He earns $48,000 annual cash plus $5,000 committee fee and stock options. Board gains compliance edge.
8-K
Warrant inducement nets $4.6M
Vivos Therapeutics induced an institutional holder to exercise existing warrants for $4.6M cash at $2.34/share on January 15, closing January 20. In exchange, it issued new 5-year and 24-month warrants for 3.96M shares at $2.09/share, plus placement agent warrants. Funds support working capital. No new equity sales until February 19.
8-K
Secures $900K bridge note
Vivos Therapeutics secured an unsecured convertible note from V-Co Investors 3 LLC on January 15, 2026, with an initial $900,000 funded and up to $5.5M maximum principal including 10% OID. The zero-interest note auto-converts dollar-for-dollar into a planned $5.5M equity raise by February 16. Bridge cash buys time. Default triggers 15% interest.
8-K
New Detroit sleep center opens
Vivos Therapeutics opened its latest sleep testing and treatment center in Auburn Hills, Michigan, on December 16, 2025, via a capital-efficient affiliation with MISleep Solutions. This contractual alliance, less intensive than its prior Las Vegas acquisition, equips the center with Vivos' FDA-cleared OSA diagnostics and therapies to tap Detroit's patient volume. Expansion accelerates. Risks include integration challenges and uncertain revenue impacts.
8-K
Vivos inks $1.5M note deal
Vivos Therapeutics secured $1.5M in gross proceeds via an unsecured promissory note to Avondale Capital on December 5, 2025, carrying a $2.1M principal with OID, backed by subsidiary AIM's guaranty. Weekly $69,778 payments start December 12; early full prepay by January 4 slashes balance by $286k. Funds fuel working capital. Default triggers 18% interest.
INSP
Inspire Medical Systems, Inc.
115.51-3.75
LIVN
LivaNova PLC
63.08+0.02
NYXH
Nyxoah SA
4.80-0.03
PETV
PetVivo Holdings Inc.
1.16-0.03
RDGL
Vivos Inc.
0.07-0.00
RMD
ResMed Inc.
247.34-5.73
RMSL
RemSleep Holdings, Inc.
0.00+0.00
SONX
Sonendo, Inc.
0.20-0.07
VANI
Vivani Medical, Inc.
1.41+0.06
VMD
Viemed Healthcare, Inc.
7.26-0.11